

AUG 21 1986

Food and Drug Administration 8757 Georgia Avenue Silver Spring MD 20910

TO: ALL MANUFACTURERS, IMPORTERS AND POTENTIAL MANUFACTURERS OF SUNLAMP PRODUCTS.

SUBJECT: POLICY ON MAXIMUM TIMER INTERVAL AND EXPOSURE SCHEDULE FOR SUNLAMP PRODUCTS.

BACKGROUND:

The amended performance standard for sunlamp products (21 CFR 1040.20) was published in the September 6, 1985 issue of the Federal Register and will become effective September 8, 1986. Any sunlamp product manufactured on or after that date must comply with the amended standard.

The ten (10) minute maximum timer interval requirement was removed from the original performance standard since there are newer sunlamp products on the market for which ten (10) minutes is not appropriate. The maximum timer interval now depends on the intensity and spectral distribution of ultraviolet (UV) radiation emission of each individual model of sunlamp product and must not exceed the maximum recommended exposure time provided on the required product warning label. Therefore, sunlamp product manufacturers must develop an exposure schedule and establish the maximum recommended exposure time (and therefore the maximum timer interval) based on the characteristics of their particular products.

The intended purposes of a sunlamp product timer are to provide for reliable control of exposures and to limit acute (and delayed) damage from unintentionally long exposures. However, the maximum timer setting should also allow for selection of exposure times needed to build up and maintain a tan. The maximum timer interval is in no way to be considered as a safe limit; all ultraviolet radiation is potentially hazardous.

The standard requires the manufacturer to provide an exposure schedule in the product warning label. The purpose of the exposure schedule is to allow a person to gradually build-up skin pigmentation and to maintain a tan while controlling the risk of acute injury and delayed adverse effects. Since the UV radiation dose that causes a barely discernible pink coloration (minimal erythemal dose or MED) is not the same for different skin types, the exposure schedule for first time users will depend on the skin type of the user. Furthermore, suberythemogenic doses of UV radiation received at 24 hours intervals initially lead to lowering of the erythema and tanning thresholds. Therefore, the exposure schedule and maximum recommended exposure time should be constrained by the potential for erythema as well as the quantity of radiation necessary to achieve and maintain a tan.

POLICY:

The Center for Devices and Radiological Health (CDRH) will use the following criteria to evaluate the adequacy of the exposure schedule and the recommended maximum exposure time (and therefore the maximum timer interval):

Page 2

1) The maximum recommended exposure time (and maximum timer interval) must not exceed a value which will result in an exposure of four (4) times the minimal erythema dose (MED) for untanned Type II skin (always burns, then tans slightly). This is based on the CDRH Erythema Action Spectrum [proposed action spectrum of Commission Internationale de L'Eclairage (CIE) modified by CDRH]. See Appendix A for the action spectrum and weighting factors and equations needed to derive it.

The formula for determining the recommended maximum exposure time, "T_a" in seconds is:

 $T_{e} = \frac{624J/M^{2}}{\sum V_{i}R_{i}}$ where Standard MED = 156J/M² at 296nm V_{i} = weighting factor R_{i}^{i} = irradiance in W/M²

2) The recommended maximum exposure time must not exceed a value which will result in an exposure of four (4) times the minimal melanogenic dose (MMD) for untanned Type II skin. This is based on the melanogenic action spectrum developed by Parrish et al (1982). See Appendix B for this action spectrum.

The formula for determining the recommended maximum exposure time, "T_m" in seconds is:

 $T_{m} = \frac{1836J/M^{2}}{\sum J_{i}R_{i}}$ where standard MMD = 459J/M² at 296nm J_{i} = weighting factor R_{i}^{i} = irradiance in W/M²

3) The recommended exposure schedule should provide for exposures of no more than 0.75 MED three times the first week, gradually increasing the exposure the following weeks until maximum tanning has occurred (approximately four weeks total) and then provide for maintenance of a tan by biweekly or weekly exposures of up to four(4) MEDs or four(4) MMDs, whichever is less.


CDRH believes that the above criteria balances the need to limit acute (and delayed) damages from unintentionally long exposure and the need to provide for single exposure durations adequate to achieve and maintain a tan.

ann B. Hall

for Walter E. Gundaker, Director Office of Compliance Center for Devices and Radiological Health

Appendices

Appendix A (page 1) ý.



The equations describing the curve are:

$$\nabla_{i}(\lambda) = 1.0 \quad (250 < \lambda < 302 \text{ nm})$$

$$\nabla_{i}(\lambda) = 10^{0.114} \quad (302 - \lambda) \quad (302 < \lambda < 325 \text{ nm})$$

$$\nabla_{i}(\lambda) = 10^{0.0161} \quad (159 - \lambda) \quad (325 < \lambda < 405 \text{ nm})$$

Section 191


14 C



[DATA]GIELYTLE ERYTHEMA, Vi CIE ACTION SPECTRUM MODIFIED BY LYTLE (CDRH) NORMALIZED TO 1 AT 250-302 NLIMIT IS 156 J/M2

WAVELENGTH	READING				
250	1	306	.3499	362	.539122E-03
251	- 1	307	.2692	363	.519508E-03
252	1	308	.207	364	.500607E-03
253	1	309	.1592	365	.482395E-03
254	1	310	.1225	366	.464844E-03
255	i	311	.09419	367	.447931E-03
256	1	312	.724399E-01	368	.431636E-03
257	-	313	.557199E-01	369	.415931E-03
258	ī	314	.428499E-01	370	.4008E-03
259	1	315	.03296	371	.386207E-03
260	i	316	.253499E-01	372	.372145E-03
261	i	317	.0195	373	.358596E-03
262	1	318	.01499	374	.345538E-03
263	1	319	.01153	375	.332958E-03
264	1	320	.887199E-02	376	.320835E-03
265	1	321	.682299E-02	377	.309154E-03
266	1	322	.005248	378	.297896E-03
267	1	323	.004036	379	.287051E-03
268	1	324	.310499E-02	380	.276601E-03
269	1	325	.212499E-02	381	.26653E-03
270	1	326	.204778E-02	382	.256828E-03
271	1	327	.197338E-02	383	.247479E-03
272	1	328	.190168E-02	384	.238469E-03
273	1	329	.183259E-02	385	.229789E-03
274	1	330	.176601E-02	386	.221424E-03
275	1	331	.170178E-02	387	.213363E-03
276	1	332	.168981E-02	388	.205596E-03
277	1	333	.158014E-02	389	.196112E-03
278	1	334	.152263E-02	390	.1909E-03
279	1	335	.146723E-02	391	.183956E-03
280	1	336	.141383E-02	392	.177267E-03
281	1	337	.136238E-02	393	.170621E-03
282	1	338	.131281E-02	394	.164608E-03
283	1	£339	.126503B-02	395	.158621E-03
284	1	340	.001219	396	.152852E-03
285	1	341	.117461E-02	397	.147293E-03
286	1	342	.113183E-02	396	.141936E-03
287	1	343	.109062B-02	399	.136774E-03
288	1	344	.10509E-02	400	.1318E-03
289	1	345	.101263E-02		1
290	1	346	.975755E-03		
291	1	347	.940221E-03		
292	1	348	.905983E-03		
293	1	349	.87299E-03		
294	1	350	.841199E-03		
295	1	351	.810582E-03		
296	1	352	.781079E-03		
297	1	353	.752649-03	•	
296	1	354	.725254E-03		
299	1	355	.698856E-03		
300	1	356	.678419E-03		
301	1	357	.649909E-03		
302	1	358	.6252915-03		
303	.7691	359	.60253E-03		
304	.5916	360	.5806E-03		
305	.455	361	.559477E-03		

Appendix B (page 1)



The MMD as function of wavelength has been interpolated (using log MMD) from the action spectrum for melanogenesis of type II skin (Parrish et al 1982)

PARRISH	MELANOGENSIS	TYPE	II	SKIN	1982	NOPMAL	17.ED TO 296 NM
WAVELEN	GTH Ji						
(mm)							
250	.378409		302	.815	6892	354	.100202E-02
251	.374828		303	.750		355	.972644E-03
252	.371248		304	.690		356	.944186E-03
253	.367714		305	.502		357	.916645E-03
254	.364225		306	.365		358	.890022E-03
255	.360783		307	.265		359	.863859E-03
256	.35734		308	.193		360	.838613E-03
257	.353943		309	.140		361	.813826E-03
- 258	.350547		310	.102		362	.789958E-03
259	.347196		311		893E-01	363	.767007E-03
260	.343891		312	.054	301	364	.747729E-03
261	.340632		313	.395	016E-01	365	.722942E-03
262	.337419		314	.341	137E-01	366	.666943E-03
263	.334206		315		593E-01	367	.615075E-03
264	.331039		316	.254	384E-01	368	.567338E-03
265	.327672		317		683E-01	369	.523272E-03
266	.327413		318		709E-01	370	.48288E-03
267	.326954		319		821E-01	371	.44547E-03
268	.326449		320		467E-01	372	.410953E-03
269	.32599		321		143E-01	373	.379097E-03
270	.325531		322		481E-01	374	.34972E-03
271	.325072		323		137E-02	375	.322593E-03
272 273	.324613 .324154		324		745E-02	376	.297577E-03
273	.324154		325 326		336E-02	377	.274534E-03
275	.323236		320 327		616e-02 748e-02	378	.253236E-03
276	.321445		328		483E-02	379 380	.233591E-03
277	.319609		329		812E-02	381	.215506E-03 .213532E-03
278	.317865		330		265E-02	382	.211558E-03
279	.316075		331		741E-02	383	.209963E-03
280	.314285		332		276E-02	384	.207702E-03
281	.312541		333		089E-02	385	.205821E-03
282	.31075		334		447E-02	386	.203939E-03
283	.351694		335		123E-02	387	.202057E-03
284	.398008		336		982E-02	388	.200221E-03
285	.450427		337		978E-02	38 9	.189296E-03
286	.509732		338		113E-02	390	.196594E-03
287	.576885		339		385E-02	391	.194804E-03
288	.652851		340		841E-02	392	.193014E-03
289	.738778		341		388E-02	393	.191224E-03
290	.836088		342		074E-02	394	.18948E-03
291 292	.861518		343		897E-02	395	.187735E-03
292	.887498		344		B12E-02	396	.186037E-03
293 294	.91435 .94212		345		864E-02 054E-02	397	.184339E-03
295	.970625		346 347		336E-02	398	.18264E-03
295	1		347 348		71E-02	399 400	.180988E-03 .179336E-03
297	.990959		349		222E-02	400	.177683E-03
298	.982054		350		825E-02	401	.176077E-03
299	.973287		351		52E-02	403	.17447E-03
300	.96429		352		307E-02	404	.172864E-03
301	.886993		353		232E-02	405	.171257E-03